How the American Glaucoma Society Annual Meeting Is Shaping Future Treatment
The American Glaucoma Society Annual Meeting is one of the most important international gatherings for glaucoma specialists. It brings together surgeons, researchers, clinicians, educators, and industry experts to discuss the latest developments in glaucoma diagnosis, monitoring, treatment, surgery, and long-term patient care.
The 2026 meeting was held from 19–22 February 2026 in Rancho Mirage, California. It followed the 2025 Washington, DC meeting, which marked the society’s 40th anniversary and placed strong emphasis on education, research, access to care, and advocacy in glaucoma management. These meetings typically showcase both established clinical practices and emerging innovations.
A key focus of these meetings is reviewing new evidence and discussing how it may influence future treatment decisions. This includes improvements in surgical techniques, advances in diagnostic technology, evolving medication options, and better ways to monitor disease progression over time.
For you as a patient, These developments matter because they can shape how the condition is detected earlier and managed more effectively. Over time, they may help reduce treatment burden, improve long-term eye pressure control, and support better strategies for preserving vision in everyday clinical care.
Why the American Glaucoma Society Meeting Matters
The American Glaucoma Society is a specialist organisation focused on improving care for people with glaucoma and those at risk of developing the condition. Its 2025 programme described its mission as improving lives through education, research, better access to healthcare, and advocacy in glaucoma care.
This mission is especially important for you because glaucoma is usually a long-term condition. It is not something that is treated once and then ignored. Most patients need regular eye pressure checks, repeat scans and visual field tests, and ongoing review of treatment plans to help protect vision over time.
When specialists attend meetings such as AGS, they are able to compare clinical evidence, discuss complex cases, review new technologies, and refine how they manage patients in everyday practice. This shared learning helps improve consistency and quality of care across different hospitals and clinics.
For you as a patient, this means the decisions made in your clinic are more likely to reflect up-to-date research, expert discussion, and a broader understanding of best practice in glaucoma management.
A Strong Focus on Patient-Centred Glaucoma Care
One of the key themes highlighted around recent American Glaucoma Society meetings is patient-centred care. Managing the condition is not only about eye pressure readings, scan results, or surgical outcomes. It is also about how the condition affects your everyday life and long-term wellbeing.
Many patients face real-world challenges such as difficulty using eye drops consistently, frequent clinic visits, anxiety about possible vision loss, and uncertainty about how the disease may progress. These factors can strongly influence how well a treatment plan works in practice, even if it looks effective on paper.
Conference discussions encourage specialists to think more carefully about these issues by focusing on communication, treatment burden, and what matters most to you as an individual patient. This helps support more balanced decisions, where medical effectiveness is considered alongside quality of life.
For you as a patient, this approach leads to more personalised glaucoma care. Treatment decisions are not based only on the disease itself, but also on how it affects your daily routine, comfort, and emotional wellbeing.
New Evidence Around First-Line Laser Treatment
Laser treatment continues to be an important topic of discussion at American Glaucoma Society (AGS) meetings. Ophthalmology Times reported that a new first-line laser treatment for glaucoma and ocular hypertension was set to be presented at the 2025 AGS Annual Meeting in Washington, DC.
This reflects a broader shift in glaucoma care, where specialists are increasingly exploring whether laser treatment can be used earlier in the treatment pathway. Instead of being reserved only for cases where eye drops are not enough or are difficult to manage, laser may sometimes be considered sooner. This includes ongoing evaluation of how effective it is, how safe it is, and how long its pressure-lowering effects may last.
For you as a patient, this development is important because it suggests that future treatment options may become more flexible. In suitable cases, earlier use of laser treatment could reduce dependence on daily eye drops and make long-term glaucoma management simpler.
However, specialists still need to carefully decide who is most likely to benefit. Laser treatment is not suitable for every type or stage of glaucoma, so careful assessment remains essential before it is recommended.
Selective Laser Trabeculoplasty and Treatment Burden
Selective laser trabeculoplasty (SLT) is a commonly used laser treatment for open-angle glaucoma and ocular hypertension. It works by targeting the trabecular meshwork, helping your eye’s natural drainage system function more effectively and lowering intraocular pressure. In many patients, SLT can reduce the need for daily eye drops, which may improve adherence and reduce long-term treatment burden. At specialist meetings such as the American Glaucoma Society, clinicians regularly review how SLT fits into modern glaucoma care and evolving treatment pathways.
- How SLT helps lower eye pressure: SLT uses targeted laser energy to stimulate the trabecular meshwork and improve fluid outflow. This supports your eye’s natural drainage system and helps reduce intraocular pressure without incisions, stitches, or implants.
- Duration of effect and repeat treatment: Conference discussions often focus on how long SLT remains effective and whether it can be safely repeated. In some people, the pressure-lowering effect may reduce over time, so repeat treatment may sometimes be considered.
- Role in modern treatment pathways: Specialists also discuss where SLT fits alongside eye drops, combination therapy, and surgical options. In many cases, it is now being considered earlier in the treatment pathway for suitable patients.
- Reducing dependence on eye drops: One of the key potential benefits of SLT is reducing reliance on daily eye drops. However, it is not suitable for everyone, and treatment decisions need to be tailored to your specific condition and eye health.
Overall, SLT is best seen as one option within a broader, personalised approach to glaucoma care. It offers a non-invasive way to lower eye pressure in selected patients, while ongoing research and clinical discussions continue to refine how and when it is best used.
Eye Drops and Adherence Challenges
Eye drops remain a central part of glaucoma treatment, but they are not always easy for you to use consistently. The American Glaucoma Society has noted that, unlike oral medications, eye drops can be difficult to administer correctly and may be less reliable as a drug delivery method in everyday life.
This is clinically important because glaucoma treatment only works well when medication is used regularly and reaches your eye properly. If doses are missed, drops are not applied correctly, or side effects such as irritation and dryness occur, the overall effectiveness of treatment can be reduced. Over time, this may affect long-term eye pressure control.
Because of this, AGS discussions often focus on ways to reduce treatment burden and improve adherence for you as a patient. This may include simplifying drop schedules, using preservative-free formulations, considering laser treatment in suitable cases, or exploring alternative delivery systems. The overall goal is to make sure your treatment is not only effective in theory, but also practical, manageable, and sustainable in real-life day-to-day use.
Sustained-Release Glaucoma Treatments
Sustained-release treatments are one of the most important future developments in glaucoma care. These approaches are designed to release medication slowly over a longer period, which may reduce or even remove the need for daily eye drops.
This could be especially helpful for you if you struggle with adherence, such as forgetting doses, finding drop application difficult, or experiencing irritation and discomfort from long-term use. It may also help make treatment more consistent, giving your doctor greater confidence that the medication is being maintained at a steady therapeutic level.
At major conferences such as AGS meetings, discussions about sustained-release systems usually focus on safety, how long they last, whether repeat treatment is needed, which patients are most suitable, and how these newer options compare with traditional eye drops in real-world use.
New Drug Development and the Glaucoma Pipeline
New drug development continues to play a major role in shaping the future of glaucoma care. A February 2026 report from Review of Ophthalmology noted that the current glaucoma pharmaceutical pipeline includes new drug molecules as well as innovative delivery systems. Some companies are also exploring treatments that may combine eye pressure reduction with possible neuroprotective effects.
This is important because most current glaucoma treatments mainly focus on lowering intraocular pressure, which is still the only proven modifiable risk factor. However, future therapies may work in more targeted ways, last longer, or provide additional support for optic nerve health alongside pressure control.
For you as a patient, this area of research is significant because it may eventually offer more treatment options and more convenient dosing schedules. It could also make long-term glaucoma management simpler and easier to maintain in daily life. Although many of these developments are still in research or clinical trial stages, they show a clear move towards improving both treatment effectiveness and quality of life for people living with glaucoma.
NCX 470 and New Pressure-Lowering Medicines
One example of newer glaucoma drug research highlighted around the 2026 American Glaucoma Society (AGS) Annual Meeting is NCX 470. Nicox announced that Phase 3 clinical trial data for NCX 470 would be presented at the 2026 meeting, including results on how well it works, its safety profile, and how it behaves in the body.
This type of research is important because glaucoma specialists depend on strong, well-designed clinical trials before new treatments can be used in routine practice. Even when early results look promising, new medications still need careful long-term evaluation for safety, consistency of effect, and how they perform in everyday real-world patients.
For you as a patient, this shows that glaucoma treatment is continuously evolving. Pressure-lowering medicines remain an active area of development, with ongoing research focused on improving effectiveness, reducing side effects, and supporting better long-term control of eye pressure.
MIGS and Modern Glaucoma Surgery
Minimally invasive glaucoma surgery (MIGS) continues to be a key topic at American Glaucoma Society (AGS) meetings. MIGS refers to a group of surgical procedures designed to lower eye pressure with less tissue disruption compared with traditional glaucoma surgery, which makes it an important development in modern glaucoma care.
The American Glaucoma Society has also previously published a position paper on MIGS to explain its role in treatment pathways and to clear up common misunderstandings. This shows how important MIGS has become in shaping current thinking about surgical options for glaucoma.
At AGS annual meetings, specialists regularly review which patients are most suitable for MIGS, how the results compare with other treatments, and when more traditional surgeries such as trabeculectomy or tube surgery may still be needed. These discussions help improve patient selection and support better decision-making in everyday clinical practice for you as a patient.
Choosing Between MIGS and Traditional Surgery
MIGS can be a useful option for selected glaucoma patients, but it is not suitable for every case. In some people, the amount of eye pressure reduction achieved with MIGS may not be enough to control more advanced or fast-progressing glaucoma.
At American Glaucoma Society (AGS) meetings, specialists often compare MIGS with more established procedures such as trabeculectomy and tube shunt surgery. These discussions usually focus on how different factors affect surgical choice, including disease stage, target eye pressure, level of visual field loss, patient age, and how many medications you are already using.
The aim of these comparisons is to support more individualised decision-making rather than a one-size-fits-all approach. By matching the procedure more closely to your specific condition, surgeons can improve the chances of long-term eye pressure control and better protection of vision.
Glaucoma Surgery Day and Practical Learning
American Glaucoma Society (AGS) meetings often place strong emphasis on surgical education and hands-on learning. Previous coverage of AGS meetings has highlighted “Glaucoma Surgery Day,” along with symposia, scientific papers, poster sessions, and lectures as key parts of the programme.
This focus on surgical learning is important because glaucoma procedures require not just technical skill, but also careful clinical judgement and post-operative management. Even small differences in surgical technique, patient selection, or follow-up care can make a real difference to outcomes, including long-term eye pressure control and complication rates.
For you as a patient, this kind of specialist training is reassuring. It supports continuous improvement in surgical expertise and helps surgeons stay up to date with the latest evidence. Over time, this can lead to safer procedures, more consistent results, and better long-term protection of your vision.
Neuroprotection and Neuroenhancement
One of the most promising future directions in glaucoma treatment is neuroprotection. This approach focuses on protecting the optic nerve and retinal ganglion cells directly, rather than only lowering eye pressure.
Coverage of the 2026 American Glaucoma Society (AGS) meeting highlighted a Clinician Scientist Lecture by Jeffrey L. Goldberg, MD, PhD, which discussed neuroprotection and neuroenhancement. A key idea was the “therapeutic window” between initial nerve cell injury and final cell death, where treatment might still help preserve function.
Although this field is still developing, it is especially relevant for you if your glaucoma continues to progress even when your eye pressure is well controlled. It suggests that pressure is not the only factor involved in the disease.
If effective treatments are developed, neuroprotection could significantly change future glaucoma care. Instead of focusing only on lowering eye pressure, treatment may also aim to directly support nerve cell survival and slow vision loss more effectively.
Gene Therapy and Optic Nerve Research
Gene therapy is an emerging area of interest in future glaucoma treatment, especially as researchers explore ways to protect the optic nerve and slow or prevent ongoing damage. This approach aims to influence the underlying biological processes involved in glaucoma, rather than focusing only on lowering eye pressure.
Coverage of the 2026 American Glaucoma Society (AGS) meeting highlighted discussions from a neuroprotection-focused lecture, including early research into gene therapy approaches that target optic nerve astrocytes. These cells help maintain the structure and environment of the optic nerve, which makes them a potential target for future treatments.
It is important for you to understand that gene therapy is not part of routine glaucoma care at present. It is still in the early or experimental research stage, and it will need extensive testing before it can be considered safe and effective for everyday clinical use.
For you as a patient, this area of research is still encouraging because it shows ongoing efforts to go beyond traditional eye pressure–lowering treatments. In the long term, it may open up new ways to protect vision at a deeper biological level.
Nicotinamide and Glaucoma Neuroprotection
Nicotinamide, a form of vitamin B3, has gained attention in glaucoma research because of its potential role in supporting retinal ganglion cell health and cellular energy metabolism. This has led to interest in whether it could help with neuroprotection in glaucoma, alongside standard eye pressure–lowering treatments.
However, major professional organisations remain cautious about how this should be used in everyday clinical practice. The American Glaucoma Society and the American Academy of Ophthalmology issued a position statement in 2025 on nicotinamide for glaucoma neuroprotection, explaining that the evidence is still developing and not yet strong enough for routine recommendation.
For you as a patient, this is an important reminder not to start supplements or alternative treatments on your own without specialist advice. Even when early research looks promising, it still needs larger and longer-term studies to confirm safety, effectiveness, and the correct dosing. At this stage, nicotinamide remains a research interest rather than a standard part of glaucoma care, and any use should be carefully guided by your eye specialist.
Imaging and Earlier Detection
Modern glaucoma care relies heavily on imaging to assess both the structure and function of the optic nerve over time. Tests such as optical coherence tomography (OCT), optic nerve photography, visual field testing, and angle assessment are essential tools that help your specialist decide whether glaucoma is stable or showing signs of progression.
At American Glaucoma Society (AGS) meetings, clinicians often review new imaging technologies as well as improved ways of interpreting scan results. This is especially important because glaucoma can progress slowly and without clear symptoms in the early stages, so subtle changes are often difficult to detect without detailed and repeated testing.
Advances in imaging may help your doctor identify progression earlier and adjust treatment sooner, before significant or irreversible vision loss occurs. This supports a more proactive and data-driven approach to glaucoma care, focused on long-term protection of your sight.
Artificial Intelligence and Digital Tools
Artificial intelligence (AI) is increasingly being explored in glaucoma care, especially for diagnosis and long-term monitoring. These digital tools may help analyse imaging tests, identify risk patterns, and detect subtle signs of progression that might not always be obvious during routine clinical review. Because glaucoma is a long-term condition that requires ongoing monitoring, AI has the potential to support more consistent and efficient analysis of large amounts of clinical data.
- Supporting scan and image analysis: AI systems can help interpret OCT scans, optic nerve photographs, and visual field tests. This may improve both the speed and consistency of detecting structural or functional changes over time.
- Identifying risk and progression patterns: One key area of development is using AI to recognise patterns that may suggest a higher risk of disease progression. This could help your clinician decide which patients may need closer monitoring.
- Understanding benefits and limitations: At meetings such as the American Glaucoma Society, specialists also discuss the limitations of AI. These include variability in data quality, differences across populations, and the need for strong validation before widespread use.
- Role in clinical decision-making: AI is designed to support, not replace, your glaucoma specialist. Final decisions about diagnosis and treatment still depend on experienced clinicians who interpret results alongside your full clinical picture.
Overall, AI and digital tools are becoming more relevant in glaucoma management, particularly for improving analysis and tracking progression over time. While these technologies may enhance consistency and support earlier detection, they remain assistive tools rather than replacements for clinical expertise. For you as a patient, this means AI is being developed to complement specialist care and help improve long-term outcomes.
Genetics and Risk Prediction
Glaucoma risk is influenced by a combination of factors, including age, intraocular pressure, family history, ethnicity, corneal thickness, and optic nerve structure. In recent years, genetics has become an increasingly important area of research, helping scientists understand why some people are more likely to develop glaucoma than others.
Some recent meeting discussions and related research have explored the idea of polygenic risk, where multiple genetic variations together contribute to an individual’s overall risk profile. This area is still developing, but it may help identify high-risk individuals earlier and more accurately than using traditional risk factors alone.
In the future, this could support a more personalised approach to glaucoma screening and monitoring. Instead of a one-size-fits-all plan, follow-up schedules and treatment decisions could be tailored more closely to your genetic and clinical risk profile, helping doctors manage glaucoma in a more targeted way.
Health Access and Equity in Glaucoma Care
Glaucoma care is not only about medical innovation or new treatments. It also depends heavily on your access to timely diagnosis, regular follow-up, and consistent long-term treatment. Without reliable access to eye care services, even the best medical advances may not fully benefit you.
The American Glaucoma Society (AGS) highlights healthcare access and advocacy as part of its core mission. This shows that their work is not limited to research, education, and surgical training. It also reflects a growing understanding that better glaucoma outcomes depend on improving how care is delivered in real-world healthcare systems.
This issue is especially important for you because glaucoma can lead to irreversible vision loss if it is not detected early or if follow-up appointments are missed. Regular monitoring plays a key role in protecting your sight over time.
Ensuring fair and equal access to care helps reduce the risk of late diagnosis and supports more stable long-term disease management. In simple terms, it helps make sure that every patient has a better chance of receiving timely and effective glaucoma care.
What AGS Meeting Themes Mean for Patients
Patients do not need to follow every technical detail presented at the American Glaucoma Society Annual Meeting. However, it is still helpful to understand that glaucoma specialists are continuously reviewing new evidence to improve how the condition is diagnosed, monitored, and treated over time.
If you are looking for glaucoma treatment in London, it is worth choosing care that places strong emphasis on thorough assessment, regular monitoring, personalised treatment planning, and clear communication. These are the foundations of good glaucoma management, regardless of whether newer technologies or treatments are being used.
The most effective glaucoma care is not based on a single procedure or prescription. Instead, it involves building a long-term, individualised plan designed to slow disease progression, preserve vision, and support patients in managing a lifelong condition as safely and consistently as possible.
FAQs:
- What is the American Glaucoma Society Annual Meeting?
The American Glaucoma Society (AGS) Annual Meeting is a major international conference where glaucoma specialists, surgeons, researchers, and clinicians come together to discuss the latest advances in diagnosis, monitoring, treatment, surgery, and long-term glaucoma care. It is widely regarded as one of the most influential meetings in glaucoma management. - When was the most recent AGS Annual Meeting held?
The 2026 AGS Annual Meeting took place from 19–22 February 2026 in Rancho Mirage, California. It followed the 2025 meeting in Washington, DC, which marked the society’s 40th anniversary and focused strongly on education, research, and improving access to glaucoma care. - Why is the AGS meeting important for glaucoma patients?
Although it is a specialist conference, the AGS meeting helps shape future clinical practice. Research and discussions presented there can influence how glaucoma is diagnosed earlier, how treatment decisions are made, and how long-term vision preservation strategies are improved in everyday care. - What new treatments were discussed at the AGS meeting?
Key topics included selective laser trabeculoplasty (SLT), minimally invasive glaucoma surgery (MIGS), sustained-release drug delivery systems, and new medications in development such as NCX 470. These reflect ongoing efforts to improve effectiveness, reduce treatment burden, and expand treatment options. - What is selective laser trabeculoplasty (SLT)?
SLT is a laser treatment that helps lower eye pressure by improving fluid drainage through the eye’s natural outflow system. It is often used in open-angle glaucoma and may reduce the need for daily eye drops in suitable patients. - What is MIGS and how is it used in glaucoma care?
Minimally invasive glaucoma surgery (MIGS) includes a group of surgical procedures designed to lower eye pressure with less tissue disruption than traditional surgery. It is typically used in mild to moderate glaucoma and is carefully compared with trabeculectomy and tube surgery at AGS meetings. - Are new glaucoma medications being developed?
Yes. Research highlighted around AGS includes new pressure-lowering drugs, longer-acting formulations, and therapies that may also support optic nerve health. Examples include emerging compounds like NCX 470, which are still undergoing clinical evaluation. - What is neuroprotection in glaucoma?
Neuroprotection refers to treatments aimed at directly protecting the optic nerve and retinal ganglion cells from damage, beyond just lowering eye pressure. Although still experimental, it is considered a promising future direction in glaucoma treatment. - How is artificial intelligence used in glaucoma care?
Artificial intelligence (AI) is being studied to analyse OCT scans, optic nerve images, and visual field tests. It may help detect subtle changes earlier, identify progression patterns, and support clinicians, but it does not replace specialist judgement. - What do AGS meeting developments mean for patients?
For patients, AGS developments mean that glaucoma care is continuously improving. While not all research becomes immediate treatment, it helps shape future approaches to diagnosis, monitoring, and therapy supporting more personalised, effective, and long-term vision protection.
Final Thoughts: What AGS Insights Mean for Future Glaucoma Care
The latest discussions from the American Glaucoma Society Annual Meeting highlight how quickly glaucoma research and treatment approaches are evolving. Advances in imaging, artificial intelligence, surgical techniques, and drug development are all contributing to a more refined understanding of how to detect glaucoma earlier and manage it more effectively over the long term. While many of these innovations are still developing, they reflect a clear shift towards more personalised and precise glaucoma care.
Despite these advancements, established treatments such as eye drops, laser therapy, MIGS, and traditional surgery remain the foundation of current clinical practice. The most important message for patients is the value of consistent monitoring and individualised treatment planning to protect vision over time. If you’re exploring whether glaucoma treatment in London could be suitable for you, feel free to contact us at Eye Clinic London to arrange a consultation.
References:
- Gupta, N. and Yücel, Y.H. (2007) Glaucoma as a neurodegenerative disease. Current Opinion in Ophthalmology, 18(2), pp.110–114. Available at: https://pubmed.ncbi.nlm.nih.gov/17301611/
- Weinreb, R.N., Aung, T. and Medeiros, F.A. (2014) The pathophysiology and treatment of glaucoma: a review. JAMA, 311(18), pp.1901–1911. Available at: https://pubmed.ncbi.nlm.nih.gov/24825645/
- Zeppieri, M. (2025) Beyond the Eye: Glaucoma and the Brain, Brains, 15(9), p.934. Available at: https://www.mdpi.com/2076-3425/15/9/934
- Chan, J.W. and colleagues (2021) Glaucoma as Neurodegeneration in the Brain, PMCID: PMC7822087. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7822087/
- Durán-Cristiano, S.C. et al. (2025) Exploring Molecular and Clinical Dimensions of Glaucoma, Int. J. Mol. Sci., 26(18), p.9109. Available at: https://www.mdpi.com/1422-0067/26/18/910